Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Amortization of Deferred Charges: 2022-2024

Historic Amortization of Deferred Charges for Madrigal Pharmaceuticals (MDGL) over the last 3 years, with Dec 2024 value amounting to $2.1 million.

  • Madrigal Pharmaceuticals' Amortization of Deferred Charges fell 31.46% to $329,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 31.44%. This contributed to the annual value of $2.1 million for FY2024, which is 13.46% down from last year.
  • As of FY2024, Madrigal Pharmaceuticals' Amortization of Deferred Charges stood at $2.1 million, which was down 13.46% from $2.4 million recorded in FY2023.
  • Madrigal Pharmaceuticals' Amortization of Deferred Charges' 5-year high stood at $2.4 million during FY2023, with a 5-year trough of $797,000 in FY2022.
  • In the last 3 years, Madrigal Pharmaceuticals' Amortization of Deferred Charges had a median value of $2.1 million in 2024 and averaged $1.8 million.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first spiked by 202.89% in 2023, then fell by 13.46% in 2024.
  • Over the past 3 years, Madrigal Pharmaceuticals' Amortization of Deferred Charges (Yearly) stood at $797,000 in 2022, then surged by 202.89% to $2.4 million in 2023, then fell by 13.46% to $2.1 million in 2024.